Mucosal Healing in Ulcerative Colitis. Pathophysiology and Pharmacology

Advances in Clinical Chemistry

Volumn 59, Issue , 2013, Pages 101-123

  Seidelin, Jakob Benedict ^a   Coskun, Mehmet ^a   Nielsen, Ole Haagen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871028685     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-405211-6.00004-8     Document Type: Chapter

References (138)

1. Froslie K.F., Jahnsen J., Moum B.A., Vatn M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
2. Dignass A.U. Mechanisms and modulation of intestinal epithelial repair. Inflamm. Bowel Dis. 2001, 7:68-77.
3. Blikslager A.T., Moeser A.J., Gookin J.L., Jones S.L., Odle J. Restoration of barrier function in injured intestinal mucosa. Physiol. Rev. 2007, 87:545-564.
4. Gitter A.H., Wullstein F., Fromm M., Schulzke J.D. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001, 121:1320-1328.
5. Iwamoto M., Koji T., Makiyama K., Kobayashi N., Nakane P.K. Apoptosis of crypt epithelial cells in ulcerative colitis. J. Pathol. 1996, 180:152-159.
6. Strater J., Wellisch I., Riedl S., Walczak H., Koretz K., Tandara A., Krammer P.H., Moller P. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 1997, 113:160-167.
7. Schulzke J.D., Ploeger S., Amasheh M., Fromm A., Zeissig S., Troeger H., Richter J., Bojarski C., Schumann M., Fromm M. Epithelial tight junctions in intestinal inflammation. Ann. N. Y. Acad. Sci. 2009, 1165:294-300.
8. Schulzke J.D., Bojarski C., Zeissig S., Heller F., Gitter A.H., Fromm M. Disrupted barrier function through epithelial cell apoptosis. Ann. N. Y. Acad. Sci. 2006, 1072:288-299.
9. Fenoglio-Preiser C., Noffsinger A.E,., Stemmermann G., Lantz P., Lindstrom M. Ulcerative colitis. Gastrointestinal Pathology-An Atlas and Text 1999, Lippincott Williams & Wilkins, Philadelphia, pp. 659-682. second ed.
10. Robinson J.M. Reactive oxygen species in phagocytic leukocytes. Histochem. Cell Biol. 2008, 130:281-297.
11. Simmonds N.J., Allen R.E., Stevens T.R., Van Someren R.N., Blake D.R., Rampton D.S. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992, 103:186-196.
12. Keshavarzian A., Sedghi S., Kanofsky J., List T., Robinson C., Ibrahim C., Winship D. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology 1992, 103:177-185.
13. Weiss S.J. Tissue destruction by neutrophils. N. Engl. J. Med. 1989, 320:365-376.
14. Faurschou M., Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect. 2003, 5:1317-1327.
15. Colgan S.P., Parkos C.A., Delp C., Arnaout M.A., Madara J.L. Neutrophil migration across cultured intestinal epithelial monolayers is modulated by epithelial exposure to IFN-gamma in a highly polarized fashion. J. Cell Biol. 1993, 120:785-798.
16. Madara J.L., Parkos C., Colgan S., MacLeod R.J., Nash S., Matthews J., Delp C., Lencer W. Cl- secretion in a model intestinal epithelium induced by a neutrophil-derived secretagogue. J. Clin. Invest. 1992, 89:1938-1944.
17. Parkos C.A., Colgan S.P., Delp C., Arnaout M.A., Madara J.L. Neutrophil migration across a cultured epithelial monolayer elicits a biphasic resistance response representing sequential effects on transcellular and paracellular pathways. J. Cell Biol. 1992, 117:757-764.
18. Breu-Martin M.T., Vidrich A., Lynch D.H., Targan S.R. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J. Immunol. 1995, 155:4147-4154.
19. Sveinbjornsson B., Rushfeldt C., Olsen R., Smedsrod B., Seljelid R. Cytotoxic effect of cytokines on murine colon carcinoma cells involves TNF-mediated apoptosis. Biochem. Biophys. Res. Commun. 1997, 233:270-275.
20. Gitter A.H., Bendfeldt K., Schulzke J.D., Fromm M. Leaks in the epithelial barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis. FASEB J. 2000, 14:1749-1753.
21. Xu X., Fu X.Y., Plate J., Chong A.S. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 1998, 58:2832-2837.
22. Koshiji M., Adachi Y., Sogo S., Taketani S., Oyaizu N., Than S., Inaba M., Phawa S., Hioki K., Ikehara S. Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2 expression. Clin. Exp. Immunol. 1998, 111:211-218.
23. Madara J.L., Stafford J. Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J. Clin. Invest. 1989, 83:724-727.
24. Hiribarren A., Heyman M., L'helgouac'h A., Desjeux J.F. Effect of cytokines on the epithelial function of the human colon carcinoma cell line HT29 cl 19A. Gut 1993, 34:616-620.
25. Niessner M., Volk B.A. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin. Exp. Immunol. 1995, 101:428-435.
26. Masuda H., Iwai S., Tanaka T., Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J. Clin. Lab. Immunol. 1995, 46:111-123.
27. Fuss I.J., Neurath M., Boirivant M., Klein J.S., de la Motte C., Strong S.A., Fiocchi C., Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 1996, 157:1261-1270.
28. Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., Mankertz J., Gitter A.H., Burgel N., Fromm M., Zeitz M., Fuss I., Strober W., Schulzke J.D. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005, 129:550-564.
29. Heller F., Fromm A., Gitter A.H., Mankertz J., Schulzke J.D. Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of pro-inflammatory interleukin-13 on epithelial cell function. Mucosal Immunol. 2008, 1(Suppl. 1):S58-S61.
30. Strater J., Hinz U., Walczak H., Mechtersheimer G., Koretz K., Herfarth C., Moller P., Lehnert T. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin. Cancer Res. 2002, 8:3734-3740.
31. Strater J., Moller P. Expression and function of death receptors and their natural ligands in the intestine. Ann. N. Y. Acad. Sci. 2000, 915:162-170.
32. Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 1989, 169:1747-1756.
33. Begue B., Wajant H., Bambou J.C., Dubuquoy L., Siegmund D., Beaulieu J.F., Canioni D., Berrebi D., Brousse N., Desreumaux P., Schmitz J., Lentze M.J., Goulet O., Cerf-Bensussan N., Ruemmele F.M. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006, 130:1962-1974.
34. Brost S., Koschny R., Sykora J., Stremmel W., Lasitschka F., Walczak H., Ganten T.M. Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease. Pathol. Res. Pract. 2010, 206:43-50.
35. Seidelin J.B., Nielsen O.H. Attenuated apoptosis response to Fas-ligand in active ulcerative colitis. Inflamm. Bowel Dis. 2008, 14:1623-1629.
36. Park S.M., Chen L., Zhang M., Shton-Rickardt P., Turner J.R., Peter M.E. CD95 is cytoprotective for intestinal epithelial cells in colitis. Inflamm. Bowel Dis. 2010, 16:1063-1070.
37. Chen L., Park S.M., Turner J.R., Peter M.E. Cell death in the colonic epithelium during inflammatory bowel diseases: CD95/Fas and beyond. Inflamm. Bowel Dis. 2010, 16:1071-1076.
38. Capaldo C.T., Nusrat A. Cytokine regulation of tight junctions. Biochim. Biophys. Acta 2009, 1788:864-871.
39. Beck P.L., Rosenberg I.M., Xavier R.J., Koh T., Wong J.F., Podolsky D.K. Transforming growth factor-beta mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells. Am. J. Pathol. 2003, 162:597-608.
40. Karrasch T., Steinbrecher K.A., Allard B., Baldwin A.S., Jobin C. Wound-induced p38MAPK-dependent histone H3 phosphorylation correlates with increased COX-2 expression in enterocytes. J. Cell. Physiol. 2006, 207:809-815.
41. Egan L.J., de Lecea A., Lehrman E.D., Myhre G.M., Eckmann L., Kagnoff M.F. Nuclear factor-kappa B activation promotes restitution of wounded intestinal epithelial monolayers. Am. J. Physiol. Cell Physiol. 2003, 285:C1028-C1035.
42. Strauch E.D., Bass B.L., Rao J.N., Vann J.A., Wang J.Y. NF-kappaB regulates intestinal epithelial cell and bile salt-induced migration after injury. Ann. Surg. 2003, 237:494-501.
43. Zou L., Sato N., Kone B.C. Alpha-melanocyte stimulating hormone protects against H2O2-induced inhibition of wound restitution in IEC-6 cells via a Syk kinase- and NF-kappabeta-dependent mechanism. Shock 2004, 22:453-459.
44. Egan L.J., Eckmann L., Greten F.R., Chae S., Li Z.W., Myhre G.M., Robine S., Karin M., Kagnoff M.F. IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc. Natl. Acad. Sci. USA. 2004, 101:2452-2457.
45. Chwieralski C.E., Schnurra I., Thim L., Hoffmann W. Epidermal growth factor and trefoil factor family 2 synergistically trigger chemotaxis on BEAS-2B cells via different signaling cascades. Am. J. Respir. Cell Mol. Biol. 2004, 31:528-537.
46. Hsu D., Fukata M., Hernandez Y.G., Sotolongo J.P., Goo T., Maki J., Hayes L.A., Ungaro R.C., Chen A., Breglio K.J., Xu R., Abreu M.T. Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab. Invest. 2010, 90:1295-1305.
47. Brandl K., Sun L., Neppl C., Siggs O.M., Le Gall S.M., Tomisato W., Li X., Du X., Maennel D.N., Blobel C.P., Beutler B. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc. Natl. Acad. Sci. USA. 2010, 107:19967-19972.
48. Cario E., Gerken G., Podolsky D.K. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007, 132:1359-1374.
49. Cario E., Gerken G., Podolsky D.K. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 2004, 127:224-238.
50. Gibson D.L., Ma C., Rosenberger C.M., Bergstrom K.S., Valdez Y., Huang J.T., Khan M.A., Vallance B.A. Toll-like receptor 2 plays a critical role in maintaining mucosal integrity during Citrobacter rodentium-induced colitis. Cell. Microbiol. 2008, 10:388-403.
51. Fukata M., Michelsen K.S., Eri R., Thomas L.S., Hu B., Lukasek K., Nast C.C., Lechago J., Xu R., Naiki Y., Soliman A., Arditi M., Abreu M.T. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G1055-G1065.
52. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306.
53. Yan S.R., Joseph R.R., Rosen K., Reginato M.J., Jackson A., Allaire N., Brugge J.S., Jobin C., Stadnyk A.W. Activation of NF-kappaB following detachment delays apoptosis in intestinal epithelial cells. Oncogene 2005, 24:6482-6491.
54. Karrasch T., Jobin C. Wound healing responses at the gastrointestinal epithelium: a close look at novel regulatory factors and investigative approaches. Z. Gastroenterol. 2009, 47:1221-1229.
55. Hagemann T., Wilson J., Kulbe H., Li N.F., Leinster D.A., Charles K., Klemm F., Pukrop T., Binder C., Balkwill F.R. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J. Immunol. 2005, 175:1197-1205.
56. Sethi G., Sung B., Aggarwal B.B. TNF: a master switch for inflammation to cancer. Front. Biosci. 2008, 13:5094-5107.
57. Coskun M., Olsen J., Seidelin J.B., Nielsen O.H. MAP kinases in inflammatory bowel disease. Clin. Chim. Acta 2011, 412:513-520.
58. Dieckgraefe B.K., Weems D.M., Santoro S.A., Alpers D.H. ERK and p38 MAP kinase pathways are mediators of intestinal epithelial wound-induced signal transduction. Biochem. Biophys. Res. Commun. 1997, 233:389-394.
59. Frey M.R., Dise R.S., Edelblum K.L., Polk D.B. p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration. EMBO J. 2006, 25:5683-5692.
60. Frey M.R., Golovin A., Polk D.B. Epidermal growth factor-stimulated intestinal epithelial cell migration requires Src family kinase-dependent p38 MAPK signaling. J. Biol. Chem. 2004, 279:44513-44521.
61. ten H.T., van den B.B., Pronk I., Drillenburg P., Peppelenbosch M.P., van Deventer S.J. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002, 50:507-512.
62. Morteau O., Morham S.G., Sellon R., Dieleman L.A., Langenbach R., Smithies O., Sartor R.B. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest. 2000, 105:469-478.
63. Kabashima K., Saji T., Murata T., Nagamachi M., Matsuoka T., Segi E., Tsuboi K., Sugimoto Y., Kobayashi T., Miyachi Y., Ichikawa A., Narumiya S. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 2002, 109:883-893.
64. Blikslager A.T., Roberts M.C., Rhoads J.M., Argenzio R.A. Prostaglandins I2 and E2 have a synergistic role in rescuing epithelial barrier function in porcine ileum. J. Clin. Invest. 1997, 100:1928-1933.
65. Goke M., Kanai M., Lynch-Devaney K., Podolsky D.K. Rapid mitogen-activated protein kinase activation by transforming growth factor alpha in wounded rat intestinal epithelial cells. Gastroenterology 1998, 114:697-705.
66. Seidelin J.B., Vainer B., Andresen L., Nielsen O.H. Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis. Virchows Arch. 2007, 451:1031-1038.
67. Seidelin J.B., Nielsen O.H. Expression profiling of apoptosis-related genes in enterocytes isolated from patients with ulcerative colitis. APMIS 2006, 114:508-517.
68. Seidelin J., Broom O., Nielsen O.H. Inhibitor of apoptosis protein-2 (cIAP2) is important for colonic epithelial wound healing. Gastroenterology 2009, 136:A693.
69. Gyrd-Hansen M., Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 2010, 10:561-574.
70. Gill C., Dowling C., O'Neill A.J., Watson R.W. Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol. Cancer 2009, 8:39.
71. Sasaki Y., Minamizawa M., Ambo A., Sugawara S., Ogawa Y., Nitta K. Cell-penetrating peptide-conjugated XIAP-inhibitory cyclic hexapeptides enter into Jurkat cells and inhibit cell proliferation. FEBS J. 2008, 275:6011-6021.
72. Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., Shiba T., Yang X., Yeh W.C., Mak T.W., Korneluk R.G., Cheng G. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 2008, 9:1371-1378.
73. Kim J., Ahn S., Ko Y.G., Boo Y.C., Chi S.G., Ni C.W., Go Y.M., Jo H., Park H. X-linked inhibitor of apoptosis protein controls alpha5-integrin-mediated cell adhesion and migration. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H300-H309.
74. Ahn S., Park H. XIAP is essential for shear stress-enhanced Tyr-576 phosphorylation of FAK. Biochem. Biophys. Res. Commun. 2010, 399:256-261.
75. von Wnuck L.K., Keul P., Ferri N., Lucke S., Heusch G., Fischer J.W., Levkau B. Integrin-mediated transcriptional activation of inhibitor of apoptosis proteins protects smooth muscle cells against apoptosis induced by degraded collagen. Circ. Res. 2006, 98:1490-1497.
76. Heazlewood C.K., Cook M.C., Eri R., Price G.R., Tauro S.B., Taupin D., Thornton D.J., Png C.W., Crockford T.L., Cornall R.J., Adams R., Kato M., Nelms K.A., Hong N.A., Florin T.H., Goodnow C.C., McGuckin M.A. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med. 2008, 5:e54.
77. Phillips A.M., Nimmo E.R., Van L.J., Drummond H.E., Smith L., Satsangi J. Detailed haplotype-tagging study of germline variation of MUC19 in inflammatory bowel disease. Inflamm. Bowel Dis. 2010, 16:557-558.
78. Kjellev S. The trefoil factor family-small peptides with multiple functionalities. Cell. Mol. Life Sci. 2009, 66:1350-1369.
79. Gronbaek H., Vestergaard E.M., Hey H., Nielsen J.N., Nexo E. Serum trefoil factors in patients with inflammatory bowel disease. Digestion 2006, 74:33-39.
80. Dignass A., Lynch-Devaney K., Kindon H., Thim L., Podolsky D.K. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J. Clin. Invest. 1994, 94:376-383.
81. Durer U., Hartig R., Bang S., Thim L., Hoffmann W. TFF3 and EGF induce different migration patterns of intestinal epithelial cells in vitro and trigger increased internalization of E-cadherin. Cell. Physiol. Biochem. 2007, 20:329-346.
82. Taupin D.R., Kinoshita K., Podolsky D.K. Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc. Natl. Acad. Sci. USA. 2000, 97:799-804.
83. Taupin D., Wu D.C., Jeon W.K., Devaney K., Wang T.C., Podolsky D.K. The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J. Clin. Invest. 1999, 103:R31-R38.
84. Kjellev S., Thim L., Pyke C., Poulsen S.S. Cellular localization, binding sites, and pharmacologic effects of TFF3 in experimental colitis in mice. Dig. Dis. Sci. 2007, 52:1050-1059.
85. Dovi J.V., Szpaderska A.M., DiPietro L.A. Neutrophil function in the healing wound: adding insult to injury?. Thromb. Haemost. 2004, 92:275-280.
86. Seidelin J.B. Colonic epithelial cell turnover: possible implications for ulcerative colitis and cancer initiation. Scand. J. Gastroenterol. 2004, 39:201-211.
87. Dignass A.U., Podolsky D.K. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology 1993, 105:1323-1332.
88. Bulut K., Meier J.J., Ansorge N., Felderbauer P., Schmitz F., Hoffmann P., Schmidt W.E., Gallwitz B. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF-beta-mediated effect. Regul. Pept. 2004, 121:137-143.
89. McKaig B.C., Makh S.S., Hawkey C.J., Podolsky D.K., Mahida Y.R. Normal human colonic subepithelial myofibroblasts enhance epithelial migration (restitution) via TGF-beta3. Am. J. Physiol. 1999, 276:G1087-G1093.
90. Goke M., Kanai M., Podolsky D.K. Intestinal fibroblasts regulate intestinal epithelial cell proliferation via hepatocyte growth factor. Am. J. Physiol. 1998, 274:G809-G818.
91. Suer S., Ampasala D., Walsh M.F., Basson M.D. Role of ERK/mTOR signaling in TGFbeta-modulated focal adhesion kinase mRNA stability and protein synthesis in cultured rat IEC-6 intestinal epithelial cells. Cell Tissue Res. 2009, 336:213-223.
92. Walsh M.F., Ampasala D.R., Rishi A.K., Basson M.D. TGF-beta1 modulates focal adhesion kinase expression in rat intestinal epithelial IEC-6 cells via stimulatory and inhibitory Smad binding elements. Biochim. Biophys. Acta 2009, 1789:88-98.
93. Owen C.R., Yuan L., Basson M.D. Smad3 knockout mice exhibit impaired intestinal mucosal healing. Lab. Invest. 2008, 88:1101-1109.
94. Tomar A., Schlaepfer D.D. Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility. Curr. Opin. Cell Biol. 2009, 21:676-683.
95. McKaig B.C., Hughes K., Tighe P.J., Mahida Y.R. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am. J. Physiol. Cell Physiol. 2002, 282:C172-C182.
96. Siegmund B. Interleukin-18 in intestinal inflammation: friend and foe?. Immunity 2010, 32:300-302.
97. Zaki M.H., Boyd K.L., Vogel P., Kastan M.B., Lamkanfi M., Kanneganti T.D. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32:379-391.
98. Dupaul-Chicoine J., Yeretssian G., Doiron K., Bergstrom K.S., McIntire C.R., LeBlanc P.M., Meunier C., Turbide C., Gros P., Beauchemin N., Vallance B.A., Saleh M. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010, 32:367-378.
99. Pickert G., Neufert C., Leppkes M., Zheng Y., Wittkopf N., Warntjen M., Lehr H.A., Hirth S., Weigmann B., Wirtz S., Ouyang W., Neurath M.F., Becker C. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 2009, 206:1465-1472.
100. Neufert C., Pickert G., Zheng Y., Wittkopf N., Warntjen M., Nikolaev A., Ouyang W., Neurath M.F., Becker C. Activation of epithelial STAT3 regulates intestinal homeostasis. Cell Cycle 2010, 9:652-655.
101. Pineton de C.G., Peyrin-Biroulet L., Lemann M., Colombel J.F. Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:15-29.
102. Nielsen O.H., Seidelin J.B., Munck L.K., Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J. Intern. Med. 2011, 270:15-28.
103. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., Lichtiger S., D'Haens G., Diamond R.H., Broussard D.L., Tang K.L., van der Woude C.J., Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 2010, 362:1383-1395.
104. Rutgeerts P., Diamond R.H., Bala M., Olson A., Lichtenstein G.R., Bao W., Patel K., Wolf D.C., Safdi M., Colombel J.F., Lashner B., Hanauer S.B. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest. Endosc. 2006, 63:433-442.
105. Lichtenstein G.R., Yan S., Bala M., Blank M., Sands B.E. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
106. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
107. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., Travers S., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., de Villiers W.J., Present D., Sands B.E., Colombel J.F. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005, 353:2462-2476.
108. Sandborn W.J., Rutgeerts P., Feagan B.G., Reinisch W., Olson A., Johanns J., Lu J., Horgan K., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., de Villiers W.J., Present D., Sands B.E., Colombel J.F. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260.
109. Sanderson J.D., Parkes G.C. Timing of surgery for inflammatory bowel disease. BMJ 2007, 335:1006.
110. Cohen R.D. The quality of life in patients with Crohn's disease. Aliment. Pharmacol. Ther. 2002, 16:1603-1609.
111. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., Sandborn W.J. The natural history of adult Crohn's disease in population-based cohorts. Am. J. Gastroenterol. 2010, 105:289-297.
112. Patrick D.L., Deyo R.A. Generic and disease-specific measures in assessing health status and quality of life. Med. Care 1989, 27:S217-S232.
113. Parente F., Molteni M., Marino B., Colli A., Ardizzone S., Greco S., Sampietro G., Foschi D., Gallus S. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. Am. J. Gastroenterol. 2010, 105:1150-1157.
114. Peyrin-Biroulet L., Oussalah A., Williet N., Pillot C., Bresler L., Bigard M.A. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011, 60:930-936.
115. Regueiro M., Schraut W., Baidoo L., Kip K.E., Sepulveda A.R., Pesci M., Harrison J., Plevy S.E. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450.
116. Rutter M.D., Saunders B.P., Wilkinson K.H., Rumbles S., Schofield G., Kamm M.A., Williams C.B., Price A.B., Talbot I.C., Forbes A. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004, 53:1813-1816.
117. Nielsen O.H., Munck L.K. Drug insight: aminosalicylates for the treatment of IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 2007, 4:160-170.
118. Sutherland L.R., Macdonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev 2006, Art. No.: CD000543.
119. Lim W.C., Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst. Rev. 2010, Art. No.: CD008870.
120. Sutherland L., Macdonald J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2006, Art. No.: CD000544.
121. Baumgart D.C., Vierziger K., Sturm A., Wiedenmann B., Dignass A.U. Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Scand. J. Gastroenterol. 2005, 40:958-964.
122. Turner D., Walsh C.M., Steinhart A.H., Griffiths A.M. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin. Gastroenterol. Hepatol. 2007, 5:103-110.
123. Mukaida N., Morita M., Ishikawa Y., Rice N., Okamoto S., Kasahara T., Matsushima K. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J. Biol. Chem. 1994, 269:13289-13295.
124. Thiele K., Bierhaus A., Autschbach F., Hofmann M., Stremmel W., Thiele H., Ziegler R., Nawroth P.P. Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease. Gut 1999, 45:693-704.
125. Goke M.N., Schneider M., Beil W., Manns M.P. Differential glucocorticoid effects on repair mechanisms and NF-kappaB activity in the intestinal epithelium. Regul. Pept. 2002, 105:203-214.
126. Jung S., Fehr S., Harder-d'Heureuse J., Wiedenmann B., Dignass A.U. Corticosteroids impair intestinal epithelial wound repair mechanisms in vitro. Scand. J. Gastroenterol. 2001, 36:963-970.
127. Landi B., Anh T.N., Cortot A., Soule J.C., Rene E., Gendre J.P., Bories P., See A., Metman E.H., Florent C. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992, 102:1647-1653.
128. Modigliani R., Mary J.Y., Simon J.F., Cortot A., Soule J.C., Gendre J.P., Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811-818.
129. Lugering A., Schmidt M., Lugering N., Pauels H.G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157.
130. ten H.T., van M.C., Peppelenbosch M.P., van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-211.
131. Geboes K., Rutgeerts P., Opdenakker G., Olson A., Patel K., Wagner C.L., Marano C.W. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr. Med. Res. Opin. 2005, 21:1741-1754.
132. Qiu W., Wu B., Wang X., Buchanan M.E., Regueiro M.D., Hartman D.J., Schoen R.E., Yu J., Zhang L. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J. Clin. Invest. 2011, 121:1722-1732.
133. Zeissig S., Bojarski C., Buergel N., Mankertz J., Zeitz M., Fromm M., Schulzke J.D. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 2004, 53:1295-1302.
134. Suenaert P., Bulteel V., Lemmens L., Noman M., Geypens B., Van A.G., Geboes K., Ceuppens J.L., Rutgeerts P. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am. J. Gastroenterol. 2002, 97:2000-2004.
135. Schroll S., Sarlette A., Ahrens K., Manns M.P., Goke M. Effects of azathioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro. Regul. Pept. 2005, 131:1-11.
136. Sinha A., Nightingale J., West K.P., Berlanga-Acosta J., Playford R.J. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N. Engl. J. Med. 2003, 349:350-357.
137. Watanabe T., Asano N., Murray P.J., Ozato K., Tailor P., Fuss I.J., Kitani A., Strober W. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J. Clin. Invest. 2008, 118:545-559.
138. Round J.L., Mazmanian S.K. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl. Acad. Sci. USA. 2010, 107:12204-12209.